Drug intelligence / Profile preview

FIB-992

Development stage: Unknown
Lead developer: Fibrocor Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

FIB-992 is a small molecule ATP-competitive kinase inhibitor characterized by exquisite selectivity. It is being developed by Fibrocor Therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF), a debilitating and deadly fibrotic disease with limited treatment options. The compound was identified through Fibrocor's translational target discovery platform, which utilizes patient-derived tissue samples from one of the world's largest fibrosis tissue biobanks. FIB-992 underwent clinical candidate nomination in 2024 and was initially planned to enter Phase 1 clinical trials in 2024, though current status indicates it remains in preclinical development as of early 2025.

Beyond the preview

Go deeper on FIB-992.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FIB-992.

Explore the full profile